Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
Polish online marketplace Erli has filed a lawsuit against dominant rival Allegro, alleging the platform abuses its market power to pressure sellers into maintaining higher prices on competing sites. Allegro denies the accusations, stating its seller benefit programs are voluntary.
Following Federal Reserve clearance and robust Q4 results, Old Second Bancorp's board authorizes a significant share repurchase program. The move amplifies discussions on whether the regional bank's stock, despite steady gains, remains undervalued or if risks in its concentrated Illinois market are being overlooked.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.
TKO Group Holdings' UFC has secured a new, multi-year marketing partnership with Good Greek Moving & Storage. The agreement will feature brand integration across UFC Fight Nights, Dana White's Contender Series, and athlete ambassador campaigns, signaling a continued push to monetize its combat sports audience beyond traditional media rights.
While market volatility tests many sectors, Hilton Worldwide Holdings has charted a remarkable course. Shareholders have seen total returns near 169% over five years, a performance fueled by a return to profitability and strategic execution that outpaced broader market trends.
Nominee Kevin Warsh's desire to aggressively shrink the Federal Reserve's multi-trillion dollar holdings collides with a financial system now structurally dependent on ample liquidity, making rapid contraction a high-risk endeavor, analysts say.
A last-minute, short-term extension of the cornerstone US-Africa trade program AGOA has been passed, averting immediate expiration but leaving businesses and governments on both continents anxious about the partnership's long-term trajectory.
Japanese apparel retailer Shimamura (TSE:8227) has completed a massive share repurchase program and reshuffled its executive team in a concentrated two-day move, signaling a strategic pivot to boost per-share metrics and long-term value.
Japan's financial giant Nomura Holdings is scaling back risk at its digital asset unit following Q3 losses, a strategic pullback that mirrors wider pain across the crypto treasury sector as Bitcoin struggles to hold key levels.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Shares of Tokio Marine Holdings (TSE:8766) have shown mixed performance recently, prompting investors to reassess the insurer's valuation amid a strong long-term track record. Analysts see potential upside from current levels, but risks remain.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
York Space Systems (NYSE: YSS) has successfully launched its initial public offering, marking a significant milestone as it begins trading on the New York Stock Exchange. The move is set to accelerate the company's expansion in satellite manufacturing and solidify its position as a key contractor for U.S. national security and defense programs in orbit.
Amid a volatile market, EFG International's consistent profit growth and significant insider holdings present a compelling case for stability-focused investors, setting it apart from riskier, loss-making ventures.
The Kospi index plunged over 5% in its sharpest drop since April, halting program trading and dragging down chip giants Samsung and SK Hynix. The selloff, fueled by global risk-off sentiment and doubts over AI spending, tests the resilience of one of the world's hottest equity markets.
